All In Biotech

Drug Trial Radar · NCT06257875

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

A Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Oct 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

156

Actual

Start

Mar 23, 2024

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 14, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). The purpose of this study is to assess how safe and effective lutikizumab is in adult participants with moderate to severe UC and how lutikizumab compares to adalimumab in the treatment of UC. Adverse events and changes in disease activity will be assessed. Lutikizumab is an investigational product being developed for the treatment of moderate to severe UC. Participants are placed in groups called treatment arms. Each group receives a different treatment. In the Induction Period, participants will be randomized into 1 of 3 arms receiving lutikizumab Dose 1, lutikizumab Dose 2, or adalimumab. In the Maintenance Period, participants who responded to lutikizumab will be randomized into 1 of 2 arms of lutikizumab maintenance and participants who responded to adalimumab will continue to receive adalimumab. All participants who did not achieve clinical response per modified Mayo Score at the end of the Induction period will receive lutikizumab. Around 200 adult participants with UC will be enrolled at approximately 200 sites worldwide. During the 12 week Induction Period, participants will be randomized to receive intravenous (IV) and subcutaneous (SC) lutikizumab or SC adalimumab. At the 12 week mark, participants who are on lutikizumab who have responded to treatment will be re-randomized to receive SC lutikizumab at different intervals until Week 52. Participants who are on adalimumab who are responding to treatment will continue to receive adalimumab. Participants who do not respond to treatment will receive SC lutikizumab. Participants who complete the Week 52 visit and in whom therapeutic benefit to study drug is confirmed by the investigator may roll over into an optional, 52-week long-term extension (LTE). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Ulcerative Colitis

Interventions

  • LutikizumabDrug

    Subcutaneous (SC) Injection

  • LutikizumabDrug

    Intravenous (IV) Infusion

  • AdalimumabDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who Achieve Endoscopic ImprovementTime frame: Week 12
  2. Number of Participants with Adverse Events (AEs)Time frame: Up to approximately Week 104

Locations

191 sites in 30 countries. Site status is shown where the registry gives one.

  • Gastro SB /ID# 258331

    Chula Vista, California

  • Southern California Res. Ctr. /ID# 258391

    Coronado, California

  • Newport Huntington Medical Group /ID# 258371

    Huntington Beach, California

  • Om Research LLC /ID# 261383

    Lancaster, California

  • UC Irvine Health /ID# 259824

    Orange, California

  • University of Colorado Hospital /ID# 258388

    Aurora, Colorado

  • Research Associates of South Florida, LLC /ID# 259813

    Coral Gables, Florida

  • University of Florida College of Medicine /ID# 260402

    Gainesville, Florida

  • Auzmer Research /ID# 260940

    Lakeland, Florida

  • Atlantic Medical Research /ID# 258507

    Margate, Florida

  • Homestead Associates in Research /ID# 260392

    Miami, Florida

  • University of Miami /ID# 258396

    Miami, Florida

  • JD Medical Group, LLC /ID# 261235

    Miami, Florida

  • Gastroenterology Group Naples /ID# 258346

    Naples, Florida

  • AdventHealth Medical Group Blood & Marrow Transplant at Orlando /ID# 260945

    Orlando, Florida

  • GCP Clinical Research, LLC /ID# 260401

    Tampa, Florida

  • Atlanta Ctr. for Gastro /ID# 259275

    Decatur, Georgia

  • Gastroenterology Associates of Central Georgia, LLC /ID# 258359

    Macon, Georgia

  • Gastroenterology Consultants, P.C /ID# 258352

    Roswell, Georgia

  • Northwestern Medicine - Northwestern Memorial Hospital /ID# 259592

    Chicago, Illinois

  • University of Chicago Medical Center /ID# 258491

    Chicago, Illinois

  • IU Health University Hospital /ID# 260398

    Indianapolis, Indiana

  • Univ Kansas Med Ctr /ID# 258489

    Kansas City, Kansas

  • Louisiana Research Center, LLC /ID# 258330

    Shreveport, Louisiana

  • Massachusetts General Hospital /Id# 259817

    Boston, Massachusetts

  • Clin Res Inst of Michigan, LLC /ID# 258386

    Chesterfield, Michigan

  • Clin Res Inst of Michigan, LLC /ID# 259267

    Chesterfield, Michigan

  • Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinic /ID# 258493

    Wyoming, Michigan

  • Mayo Clinic - Rochester /ID# 258402

    Rochester, Minnesota

  • Univ New Mexico /ID# 258490

    Albuquerque, New Mexico

  • NY Scientific /ID# 260937

    Brooklyn, New York

  • NYU Langone Long Island Clinical Research Associates /ID# 258504

    Lake Success, New York

  • Weill Cornell Medicine/NYP /ID# 258953

    New York, New York

  • Columbia University Medical Center /ID# 258496

    New York, New York

  • Atrium Health /ID# 258506

    Charlotte, North Carolina

  • DJL Clinical Research, PLLC /ID# 259465

    Charlotte, North Carolina

  • Atrium Health Wake Forest Baptist Medical Center /ID# 260387

    Winston-Salem, North Carolina

  • Plains Clinical Research Center, LLC /ID# 258502

    Fargo, North Dakota

  • Digestive Disease Specialists /ID# 258499

    Oklahoma City, Oklahoma

  • Digestive Health Associates of Texas (DHAT) Research Institute - Garland /ID# 258358

    Garland, Texas

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.